Aten Therapeutics Competitors and Similar CompaniesClear all

Aten Therapeutics's competitors and similar companies include Recordati, Agios Pharmaceuticals, Debiopharm and Helsinn Group.

	Aten Therapeutics Aten Therapeutics is a biotechnological company.	Recordati Recordati Industria Chimica e Farmaceutica is a company that manufactures and commercializes pharmaceutical products.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.	Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections.	Helsinn Group Helsinn Group is a pharmaceutical company that focuses on therapeutic and supportive care products for cancer.
Founding Date	Founding Date 2005	Founding Date 1926	Founding Date 2008	Founding Date 1979	Founding Date 1976
Type	Type Private	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma
Locations	Locations Edinburgh, GB HQ Edinburgh, GB London, GB	Locations Milan, IT HQ Campoverde, IT	Locations Cambridge, US HQ	Locations Lausanne, CH HQ Oss, NL	Locations Pazzallo, CH HQ Shanghai, CN Monaco, MC Biasca, CH Woodbridge Township, US
Employees	Employees 4	Employees 4,580	Employees 53611% increase	Employees 4771% decrease	Employees 3731% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 12 b	Valuation ($) 2.7 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €2.6b (FY, 2025)	Revenue (est.) $54m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €607.7m (FY, 2025)	Cost of goods $6.3m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €2b (FY, 2025)	Gross profit $47.7m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income €443.6m (FY, 2025)	Net income ($412.8m) (FY, 2025)	Net income N/A	Net income N/A